Eli Lilly’s antibody drug lowers viral loads and improves symptoms in mildly ill COVID-19 patients
Eli Lilly & Co’s coronavirus antibody treatment can almost completely reduce viral loads in COVID-19 patients to zero and lowers the risk of hospitalization. Researchers found that mildly and moderately ill patients given a high dose of the antibody, LY-CoV555 (also known as bamlanivimab), had viral loads that were 3.4 times lower than those who … Read more